{'52WeekChange': -0.15770465,
 'SandP52WeekChange': 0.0644362,
 'address1': '2100 Wharton Street',
 'address2': 'Suite 701',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 46,
 'askSize': 1200,
 'averageDailyVolume10Day': 98437,
 'averageVolume': 188639,
 'averageVolume10days': 98437,
 'beta': 1.060426,
 'beta3Year': None,
 'bid': 41.92,
 'bidSize': 1100,
 'bookValue': 11.42,
 'category': None,
 'circulatingSupply': None,
 'city': 'Pittsburgh',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 42.62,
 'dayLow': 40.36,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -24.411,
 'enterpriseToRevenue': None,
 'enterpriseValue': 546362240,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 43.417145,
 'fiftyTwoWeekHigh': 66.85,
 'fiftyTwoWeekLow': 31.89,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11974302,
 'forwardEps': -2.93,
 'forwardPE': -14.327644,
 'fromCurrency': None,
 'fullTimeEmployees': 51,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.32196,
 'heldPercentInstitutions': 0.68254995,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/krystalbio.com',
 'longBusinessSummary': 'Krystal Biotech, Inc., a gene therapy company, '
                        'develops and commercializes medicines for patients '
                        'suffering from skin diseases in the United States. '
                        "The company's lead product candidate is beremagene "
                        'geperpavec (B-VEC), which has completed Phase I/II '
                        'clinical study to treat dystrophic epidermolysis '
                        'bullosa. It is also involved in developing KB105 that '
                        'is in Phase I/II clinical study for treating patients '
                        'with deficient autosomal recessive congenital '
                        'ichthyosis; KB301, which is in preclinical stage for '
                        'treating aesthetic skin conditions; KB104 that is in '
                        'preclinical stage for the treatment of Netherton '
                        'Syndrome; and KB5xx for treating chronic skin '
                        'diseases, which is in discovery stage. The company '
                        'was formerly known as Krystal Biotech, LLC and '
                        'changed its name to Krystal Biotech, Inc. in March '
                        '2017. Krystal Biotech, Inc. was founded in 2015 and '
                        'is headquartered in Pittsburgh, Pennsylvania.',
 'longName': 'Krystal Biotech, Inc.',
 'market': 'us_market',
 'marketCap': 825360384,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_534062888',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -20318000,
 'nextFiscalYearEnd': 1640908800,
 'open': 40.94,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '412 586 5830',
 'previousClose': 41.22,
 'priceHint': 2,
 'priceToBook': 3.676007,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 42.62,
 'regularMarketDayLow': 40.36,
 'regularMarketOpen': 40.94,
 'regularMarketPreviousClose': 41.22,
 'regularMarketPrice': 40.94,
 'regularMarketVolume': 81333,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17385800,
 'sharesPercentSharesOut': 0.0805,
 'sharesShort': 1582677,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1176426,
 'shortName': 'Krystal Biotech, Inc.',
 'shortPercentOfFloat': 0.1062,
 'shortRatio': 7.97,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'KRYS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.221,
 'twoHundredDayAverage': 48.999714,
 'volume': 81333,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.krystalbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '15203'}